A Phase I/II Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of HB0028 in Patients With Advanced Solid Tumors
Latest Information Update: 02 Jul 2024
At a glance
- Drugs HB 0028 (Primary)
- Indications Adenocarcinoma; Carcinoma; Cervical cancer; Gastric cancer; Head and neck cancer; Liver cancer; Lung cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Renal cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man
- Sponsors Huabo Biopharm
Most Recent Events
- 04 Jun 2024 Results (data cutoff date of DEC 25,2023, n= 16 patients) presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 30 Jan 2024 New trial record